Quanterix (QTRX) Q3 2024 earnings summary

Executive summary

• Achieved sixth consecutive quarter of double-digit revenue growth, with Q3 2024 revenue up 13% year-over-year to $35.8 million, driven by strong Accelerator Lab, consumables, and service revenue, while instrument sales declined.

• Gross margin improved on a non-GAAP basis to 53.4%, with GAAP gross margin at 58.9%; operating loss narrowed to $11.2 million, while net loss was $8.4 million.

• Maintained a strong liquidity position with $293.5–$296.1 million in cash and equivalents, and reduced cash usage to $3.3 million in Q3.

• Advanced strategic priorities in neurology, immunology, oncology, and Alzheimer's diagnostics, launching 16 new products year-to-date, including LucentAD Complete.

• Announced restatement of prior financials due to inventory valuation errors and internal control weaknesses, with no material impact expected on total revenues or cash.

Financial highlights

• Q3 2024 total revenue: $35.8 million (+13% year-over-year); nine months ended September 30, 2024: $102.3 million (+13% YoY).

• GAAP gross profit: $21.1 million (58.9% margin); non-GAAP: $19.1 million (53.4% margin).

• Net loss for Q3 2024: $8.4 million; operating loss: $11.2 million.

• Cash, cash equivalents, and marketable securities at quarter-end: $293.5–$296.1 million.

• Net cash outflow: $3.3 million in Q3 2024.

Outlook and guidance

• Reaffirmed full-year 2024 revenue guidance of $134–$138 million, representing 11% growth at the midpoint.

• Reaffirmed GAAP gross margin guidance of 57–61% and non-GAAP gross margin of 51–55%.

• No change to expected 2024 cash burn of approximately $30 million.

• No material revenue expected from Lucent Diagnostics tests until 2025 or later.

• Research-use only business expected to achieve cash flow break-even at $170–$190 million in revenue.